|
RFX5 |
regulatory factor X5 |
|
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
- Bare lymphocyte syndrome (BLS) type2
|
|
RHD |
Rh blood group D antigen |
- Rhesus blood group biosynthesis
|
|
|
|
RPS24 |
ribosomal protein S24 |
- L13a-mediated translational silencing of Ceruloplasmin expression
- Peptide chain elongation
- SRP-dependent cotranslational protein targeting to membrane
- SRP-dependent cotranslational protein targeting to membrane
- Viral mRNA Translation
- Selenocysteine synthesis
- Major pathway of rRNA processing in the nucleolus and cytosol
- Translation initiation complex formation
- Formation of a pool of free 40S subunits
- Formation of the ternary complex, and subsequently, the 43S complex
- Ribosomal scanning and start codon recognition
- GTP hydrolysis and joining of the 60S ribosomal subunit
- Eukaryotic Translation Termination
- Regulation of expression of SLITs and ROBOs
- Response of EIF2AK4 (GCN2) to amino acid deficiency
- SARS-CoV-1 modulates host translation machinery
- SARS-CoV-2 modulates host translation machinery
- Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA
- ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA
|
|
- Diamond-Blackfan anemia (DBA)
|
|
RTP2 |
receptor transporter protein 2 |
- Expression and translocation of olfactory receptors
|
|
|
|
SCAMP5 |
secretory carrier membrane protein 5 |
|
|
|
|
SEC22B |
SEC22 homolog B, vesicle trafficking protein |
- ER-Phagosome pathway
- COPII-mediated vesicle transport
- Cargo concentration in the ER
- COPI-dependent Golgi-to-ER retrograde traffic
|
|
|
|
SELENOK |
selenoprotein K |
|
|
|
|
SERP2 |
stress associated endoplasmic reticulum protein family member 2 |
|
|
|
|
SFTPC |
surfactant protein C |
- Surfactant metabolism
- Defective pro-SFTPC causes SMDP2 and RDS
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
|
|
- Pulmonary surfactant metabolism dysfunction (SMDP)
|
|
SIGLEC1 |
sialic acid binding Ig like lectin 1 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
- Beta-D-Glucose
- N-acetyl-alpha-neuraminic acid
|
|
|
SLC22A1 |
solute carrier family 22 member 1 |
- Neurotransmitter clearance
- Norepinephrine Neurotransmitter Release Cycle
- Abacavir transmembrane transport
- SLC-mediated transport of neurotransmitters
- SLC-mediated transport of organic cations
- Ciprofloxacin ADME
|
|
|
|
SLC30A8 |
solute carrier family 30 member 8 |
- Insulin processing
- Zinc efflux and compartmentalization by the SLC30 family
|
|
- Type II diabetes mellitus
|
|
SLC35B4 |
solute carrier family 35 member B4 |
- Transport of nucleotide sugars
|
|
|
|
SLC35E4 |
solute carrier family 35 member E4 |
|
|
|
|
SLC38A7 |
solute carrier family 38 member 7 |
|
|
|
|
SLC61A1 |
solute carrier family 61 member 1 |
|
|
|
|
SMCO4 |
single-pass membrane protein with coiled-coil domains 4 |
|
|
|
|
SMIM1 |
small integral membrane protein 1 (Vel blood group) |
|
|
|
|
SOS1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
- SOS-mediated signalling
- SOS-mediated signalling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Signalling to RAS
- Signalling to RAS
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- NRAGE signals death through JNK
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- SHC-related events triggered by IGF1R
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- NCAM signaling for neurite out-growth
- G alpha (12/13) signalling events
- Activation of RAC1
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- MET activates RAS signaling
- RET signaling
- Interleukin-15 signaling
- RAC1 GTPase cycle
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- Interleukin receptor SHC signaling
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Potential therapeutics for SARS
- Signaling by CSF1 (M-CSF) in myeloid cells
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- RHOU GTPase cycle
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- GPER1 signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Degradation of CDH1
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|